The Biden administration says popular weight loss drugs like Ozempic and Wegovy have been added to Medicare’s list of ...

The negotiated prices of 15 Medicare Part D drugs, which include several blockbusters, will go into effect in 2027.

The Centers for Medicare and Medicaid Services (CMS) released its second round of drug negotiation targets, a list of 15 ...

Ozempic was one of the 15 drugs selected for the 2027 Medicare drug price negotiation program three days before ...

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...

Novo Nordisk said that patients taking a higher dose of its blockbuster Wegovy obesity shot lost more weight than those on a lower dose without experiencing an increase in side-effects, according to a ...

The list of 15 drugs ( up from 10 in 2023) includes four oncology drugs, three drugs targeting diabetes, two focused on COPD, ...

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...

Announcing the 15 medicines chosen for the second round of negotiations is one of the Biden administration’s final health ...

Popular but pricey weight-loss drugs Ozempic and Wegovy are among the 15 medications whose prices will be subject to direct negotiations between Medicare and drug makers.

Drugmakers will have until the end of February to decide whether they want to participate in the second round of Medicare ...